cyrilzakka/clinical-trials huggingface dataset:
Appropriate Complmentary Feeding Strategies in Infants

The purpose of this study has been to understand the prevalence of under nutrition and develop effective interventions for improving growth and micronutrient status of infants receiving complementary foods.

In this community based randomized clinical trial, the nutrition education package implemented aimed to improve hematological parameters including the micronutrient status and to see effect on growth indicators.

Transition from exclusive breast feeding to complementary feeding poses many challenges as the demand for nutrients necessary for optimum growth and development increases steadily. Malnutrition and micronutrient malnutrition can be inter-generational and affect pregnant mothers and consequently the baby may be born with deficient micronutrient stores, especially those of iron. This deficiency can be further exacerbated by sub-optimal practices of breast feeding. Globally, iron deficiency is the most common cause of anemia estimated to affect nearly 2 billion people especially preschool children. In Pakistan, 56 % of children under the age of five years are estimated to have iron deficiency anemia and 13 % are also severely malnourished. These deficiencies affect not only physical growth but also mental development with significant impact on immunity and increased burden of infections. It is uncertain what the most appropriate intervention strategy is and a wide range of options are mentioned including dietary diversification through nutrition education, provision of fortified foods, iron supplementation and home-based fortification of complementary foods with micronutrient powders such as Sprinkles.

In an effort to understand the prevalence of under nutrition and develop effective interventions for improving growth and micronutrient status of infants receiving complementary foods, I undertook a prospective community-based randomized controlled efficacy trial in a representative urban population of Karachi. Infants and mothers were identified after birth and enrolled in the study to receive one of the interventions through community health workers at the age of six months. The enrolled infants were placed in three groups - defined as Nutr Education (Nutr Edu), Oral iron supplementation (OIS) and Multiple micronutrient fortification (MMF). Nutrition education component was common to all the groups. Through nutritional education sessions held in the community, dietary diversification along with continuation of breast feeding was stressed to enhance the intake of diet, rich in iron, and other micronutrients. A cohort of 451 infants (177 in group Nutr Edu, 141 in group OIS and 133 in MMF) were followed for three months (till the end of treatments) for growth, micronutrient status, and morbidity rate and thereafter followed for another three months to evaluate anthropometric parameters.

Eligibility Criteria:
Inclusion Criteria:

* All children between the age of 6 months to 8 months.

Exclusion Criteria:

* Children who are sick to an extent that cannot take anythign oral were excluded from this study.
Treatment of Occult Inguinal Hernias

Inguinal hernias are a common surgical problem. Best management of occult inguinal hernias, defined as hernias unable to be felt on physical exam, is unknown. From prior studies we know that most inguinal hernias will eventually become symptomatic and require surgery (70%). However, doing a repair on a very small, occult hernia may open the patient up to surgical complications, like chronic pain, earlier than necessary. This will be a multi-center randomized controlled trial of surgical repair versus expectant management of occult inguinal hernias. Patients undergoing laparoscopic unilateral inguinal hernia repair will be included. At the time of surgery, the surgeon will determine if there is an occult hernia contralateral side. If present, patients will be randomized to repair of the occult side or expectant management of the occult side. After 1 year post-operative data has been assessed, a decision tool will be created and administered to patients to aid in their decision making about treatments for their hernia.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Patients undergoing unilateral laparoscopic inguinal hernia repair, found to have a contralateral occult inguinal hernia

Exclusion Criteria:

* Patient has life expectancy of less than 2 years
* Patients unlikely to follow-up (e.g. live out of state, unable to be reached by phone/e-mail
* Non-English and Non-Spanish speakers
* Pregnant or breast-feeding patients
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.

Primary Objective:

1. To assess if increased lactate production measured by HP 13C MRI occurs in suspected ovarian cancer patients who will undergo surgery
2. To evaluate the proportion of increased lactate production in the ovaries measured by HP 13C MRI in low/high ovarian cancer risk patients.

Secondary Objectives:

1. Correlate HP-MR findings to metabolomics, immune profiles, and blood biomarkers of patients undergoing surgical resection.
2. Demonstrate the feasibility and utility of metabolic imaging with HP 13C pyruvate MR in patients with suspected ovarian cancer
3. Correlating imaging findings such as enhancement pattern, ADC values, and advanced image analytics such as texture with pathology and genetic analysis for patients who will undergo surgical resection.

Eligibility Criteria:
Inclusion Criteria:

For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson:

1. Patients with a first degree relative (mother, sister, or daughter) with ovarian cancer or
2. A personal history of breast cancer before age 40 or
3. A personal history of breast cancer diagnosed before age 50, and one or more close relatives diagnosed with breast or ovarian cancer at any age. Two or more close relatives diagnosed with breast cancer before age 50 or with ovarian cancer diagnosed at any age or
4. Ashkenazi Jewish heritage and a personal history of breast cancer before age 50 or
5. Ashkenazi Jewish heritage and a first- or second-degree relative diagnosed with breast cancer before age 50 or with ovarian cancer at any age or
6. Presence of a BRCA1 or BRCA2 mutation or
7. Presence of a mismatch repair gene mutation associated with a hereditary cancer syndrome known as Hereditary Non-Polyposis Colon Cancer (HNPCC)/Lynch syndrome. For the second cohort- 10 Patients will be enrolled who present to MD Anderson for a pelvic ultrasound or have an outside ultrasound or imaging study without a mass or have an adnexal mass (benign) on outside imaging and do not have a high risk for ovarian cancer.

For the third cohort of patients:

10 patients who have suspicion of ovarian malignancy on conventional imaging and will be undergoing surgical resection will be included.

Exclusion Criteria:

(all cohorts)

1. Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.
Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage

The purpose of this observational study was to compare perihematomal edema and short-term prognosis in patients with intracerebral hemorrhage carrying the APOE-ε3 and APOE-ε4 genes. The main questions it aims to answer are:

* Exploring whether patients carrying the ApoE-ε4 gene have more perifocal perihematomal edema after intracerebral hemorrhage than patients with the ApoE-ε3 gene.
* ApoEε4 gene has worse short-term prognosis than ApoEε3 gene in intracerebral hemorrhage patients.

All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.Some ICH patients were evaluated for Stereotactic minimally invasive surgery (sMIS) treatment by two experienced neurosurgeons.


Eligibility Criteria:
Inclusion Criteria:

* Relevant diagnosis of supratentorial ICH was confirmed through unenhanced CT scanning.
* Patients were distinguished based on venous blood collection, with the presence of the ApoE-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) gene (ApoE-ε4 genotype) and patients harboring the ApoE-ε3 (ε3/ε3) gene (non-ApoE-ε4 genotype).

Exclusion Criteria:

* Patients with infratentorial ICH.
* Patients with ApoE-ε2 (ε2/ε2) based on venous blood collections.
* Younger than 18 years of age.
* ICH caused by trauma, anticoagulation therapy, or antiplatelet therapy.
* Patients admitted to the hospital with diseases that might impact inflammatory responses, such as infective meningitis and systemic infections.
* Patients with previous residual neurological deficits following a stroke.
* Patients with combined tumours, severe liver and kidney dysfunction, cardiac insufficiency.
Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation

This study aims to see how feasible a mobile app based virtual reality program for smoking cessation (MindCotine) would be among Stanford cancer center patients


Eligibility Criteria:
Inclusion Criteria:

* Daily cigarette smoker or some day smoker (\>9 cigarettes per week)
* Age 18+
* English or Spanish fluent
* Smartphone compatibility
* Available to interact with a smartphone app for 6-weeks
* Available to complete the EOT assessment at end of 6-weeks
* Ability to understand and the willingness to personally sign the written IRB-approved informed consent document.
* Confirm phone, email, address during consent

Exclusion Criteria:

* Ever had epilepsy
* Less than 10 cigarettes per week
* Not English or Spanish fluent
* No smartphone compatibility
* Unavailable to interact with the VR program,
* Unavailable to answer questions about the intervention post-treatment
Subcutaneous Nerve Stimulation for Failed Back Surgery Syndrome (FBSS) Patients

The purpose of this study is to assess the safety and efficacy of Subcutaneous Nerve Stimulation (SQS) (also known as Peripheral Nerve Stimulation \[PNS\]) in the reduction of chronic, intractable post-surgical back pain in adults.

This study is a multi-center, prospective, randomized (1:1) parallel-group design.

Eligibility Criteria:
Key Inclusion Criteria:

* Have persistent back pain for at least 6 months
* Had back surgery at least 6 months ago
* Have tried pain medications and physical therapy
* Read and understand written English or Spanish
* Male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using a medically-acceptable method of birth control during study participation
* Willing and able to undergo surgical implant procedure, attend visits as scheduled, and comply with the study requirements
* Have an expected lifespan greater than 12 months

Key Exclusion Criteria:

* Have leg pain in addition to back pain.
* Currently enrolled in or plan to enroll in another drug and/or device study
* Have peripheral vascular disease, peripheral neuropathy, small-fiber neuropathy, or fibromyalgia
* Have an active systemic infection or are immunocompromised
* Will be exposed to diathermy or anticipate needing a full-body MRI scan
* Currently have an implantable cardiac pacemaker, defibrillator, or neurostimulator
* Treated with spinal cord stimulation, peripheral nerve stimulation, an intrathecal drug delivery system or requires additional back surgery
Perceptions and Representations of Cancer Chemotherapy

Qualitative study on data from interviews such patients, relatives and doctors involved in the implementation of cancer care. Framework type of method using grounded theory

The word chemotherapy itself, because it belongs to the secular knowledge and therefore Doxa is a hard word, which stores what it is stable, common and therefore impersonal. It has the properties of a symbol, that is to say that joint several meanings, some of which are contradictory.

The objective of the research:

To determine the perceptions and representations of chemotherapy, its physical impacts, psychological and relational.

To qualitatively compare the performances of chemotherapy as it has an end as scheduled for adjuvant chemotherapy, or endless precise as in the palliative chemotherapy

Eligibility Criteria:
Inclusion Criteria:

* 30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment
* 30 significant others (relatives) major applicant lung cancer patients chemotherapy either palliation or as adjuvant to surgery
* 15 Doctors oncologists performing either chemotherapy as palliative or adjuvant as surgical treatment

Exclusion Criteria:

* NA
EEG Monitoring Under Anaesthesia in Children: Towards Personalized Anaesthesia Care

Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.

The investigators aim to determine if EEG-guided anaesthesia using the Masimo Sedline Root monitor will result in different anaesthetic requirements, different anaesthetic depth, and emergence characteristics in children under 16 years of age.

200 children under 16 years undergoing routine general anaesthesia under sevoflurane will be randomized to either EEG monitoring or routine care. We will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.

Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.

At present, monitoring of the brain under anaesthesia is not routinely employed. Since every patient is different and the way their brain response to anaesthetic drugs is different, it is important to adjust the patients' anaesthetic depth according to their brains' response, rather than only relying on routine cardiorespiratory parameters. This is important particularly for children, whose physiological responses and electroencephalographic recordings (EEG) differ from that of adults.

200 children under 16 years undergoing routine sevoflurane general anaesthesia will be randomized to either EEG-guided anaesthesia or routine care. The investigators will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Patients 1-16 years old scheduled to undergo general sevoflurane anaesthesia for surgeries or procedures anticipated to last at between 30 minutes to 4 hours.

Exclusion Criteria:

* Patients with neurological diseases including seizure disorders
* Patients with developmental delay or genetic syndromes
* Patients with craniofacial deformities where it is not possible to place the EEG sensors
* Patients with severe eczema or skin allergy or atopy.
* Patients who are having craniofacial surgery where it is not possible to place the EEG sensors
* Patients whose foreheads are too small to accommodate the EEG sensors.
* Patients who require sedative premedications.
French Version of the Scales of Fear of Hypoglycaemia in Children With Type 1 Diabetes and Their Parents

Type 1 diabetes usually appears brutally in children or young adults. While many factors of poor glycemic balance have been identified in the literature (age, socio-cultural and socio-economic level, family structure, adherence etc.), it turns out that hypoglycemia is the most common acute complications. It would be an important physiological and psychological barrier for the patient and his parents to manage this diabetes, the latter seeking to keep the blood glucose levels above the objectives in order to avoid the occurrence of a hypoglycemia, especially nocturnal.

If there is a questionnaire currently validated as a tool to measure the fear of hypoglycemia (HFS, Hypoglycemia Fear Survey is available in three versions: L'HFS-Child (HFS-C) for children over 6 years old, HFS-Parents of Young children ( HFS-PYC) for parents of young children (under 8 years of age) and HFS-Parents (HFS-P)) for parents of children over 8 years of age, on the other hand, there are no French and no French studies have evaluated the prevalence and impact of the fear of hypoglycemia in French patients with type 1 diabetes.

It is therefore essential to use a reliable and valid tool to identify patients affected by the fear of hypoglycemia, which can be an obstacle to improve glycemic control and to an optimum quality of life. Having a tool in French and validated on the scientific level would allow to propose adapted therapeutic treatments (psychological follow-up, individual or collective sessions of therapeutic education, material assistance (sensor of blood glucose, pump with insulin stop...) In order to both improve metabolic balance while increasing the quality of life of patients by lowering secondary anxiety to hypoglycemia


Eligibility Criteria:
Inclusion Criteria:

* Age between 2 and 18 years
* Type 1 diabetes defined by an hyperglycemia higher than 2g/l, polyuria, polydipsia and positive antibody
* insulin-treated type 2 diabetes by daily injections or insulin pump

Exclusion Criteria:

* Trouble to read
* Trouble to understand
* Trouble to answer to the questionnaire
* Opposition.
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy


Eligibility Criteria:
Inclusion Criteria:

* Aged at least eighteen years old.
* Able to provide written informed consent.
* Have a medical diagnosis of nickel allergy with at least a +2 reaction on the
* ICDRG scoring system when challenged with nickel.
* Fitzpatrick skin type 1-4.
* Able to speak and understand Danish.

Exclusion Criteria:

* Received any topical immunomodulating or immunosuppresive treatment on the lower back two weeks prior, or applied crème/lotion on the lower back 24 hours prior to day 0.
* Received systemic immunomodulating or immunosuppressive treatment four weeks prior to day 0.
* Any skin lesions at the area of interest such as nevi, scar tissue or pigment changes.
* Dermatitis and/or infection.
* Recent (3 months or less) administration of a live virus vaccine.
* Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating.
* Taking part in any other intervention study.
* Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study (e.g. condition requiring long term or frequent oral steroid use).
* Presence of any condition or use of any medication which precludes the use of the study drug.
* Allergy to any of the ingredients in the drug.
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

Eligibility Criteria:
Inclusion Criteria:

* The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China;
* Participants aged over 18;
* Written the informed consent.

Exclusion Criteria:

* Hypersensitivity to chloroquine or hydroxychloroquine;
* Women during pregnancy;
* Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
* Participants with retinal disease, hearing loss;
* Participants with severe neurological and mental illness;
* Subjects were considered to be unable to complete the study, or not suitable for the study by researchers.

Exit criteria:

* Subjects asked to withdraw the study
* Subject will benefit if withdraw according to researchers' suggestions
Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell Carcinoma

the investigators randomly divide the eligible objects into two groups:1. objects in this group will first receive OE endoscopy observation and subsequent white light imaging(WLI) observation during oropharynx and hypopharynx; 2. objects in this group will first receive WLI observation and subsequent OE observation during oropharynx and hypopharynx. Then, the investigators will compare the detect rate of oropharyngeal and hypopharyngeal superficial squamous cell carcinoma of two groups to find if OE endoscopy can improve the detect rate of oropharyngeal and hypopharyngeal superficial squamous cell carcinoma in esophageal cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* order than 18 years old
* Previous or current histopathological pathology confirmed the presence of esophageal squamous cell carcinoma

Exclusion Criteria:

* Previously confirmed pharynx/oropharyngeal squamous cell carcinoma
* Advanced pharynx/hypopharyngeal squamous cell carcinoma
* Pregnant women and lactating women
* pharyngeal or esophageal stenosis, esophageal varices, or active digestive tract hemorrhage influence the observation or fail to obtain pathological diagnosis
* Previous chemotherapy or radiation therapy affected observation
* Not completed gastroscopy or refused to take biopsy for various reasons
* Mental illnesses such as anxiety and depression affect the endoscopic observation
* Severe systemic disease, can not tolerate gastroscopy
* Refusal to sign informed consent books